Peripheral blood test provides a practical method for glioma evaluation and prognosis prediction

Wang, Zhiliang; Zhang, Chuanbao; Liu, Yuqing; Wang, Zheng; Jiang, Tao

doi:10.1111/cns.13120

Cited by 23 publications

(34 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinically, the WHO stage system is commonly used for prognostic prediction in glioma patients. However, it has been suggested that prognostic prediction in glioma patients may be complicated, and the prognosis in patients with same WHO stage glioma can vary dramatically [6,7]. Therefore, uncovering novel prognostic factors remains important for improving the quality of care for glioma patients.…”

Section: Introductionmentioning

confidence: 99%

Expression of CD44 and the survival in glioma: a meta-analysis

Song

et al. 2020

Bioscience Reports

View full text Add to dashboard Cite

Background: Higher tumor expression of CD44, a marker of cancer stem cells (CSCs), is associated with poor overall survival (OS) in various cancers. However, the association between CD44 and poor OS remains inconsistent in glioma. We aimed to evaluate the potential predictive role of CD44 for prognosis of glioma patients in a meta-analysis. Methods: Observational studies comparing OS of glioma patients according to the level of CD44 were identified through searching PubMed, Embase, and Cochrane’s Library databases. Meta-analyses were performed with a random- or fixed-effect model according to the heterogeneity. Subgroup analyses were performed to evaluate the influences of study characteristics. Results: Eleven retrospective cohort studies were included. Results showed that increased CD44 expression in tumor predicted poor OS in glioma patients (hazard ratio [HR]: 1.42, 95% confidence interval [CI]: 1.02–1.97, P=0.04). Subgroup analyses showed that higher tumor CD44 expression significantly predicted poor OS in patients with World Health Organization (WHO) stages II–III glioma (HR: 2.99, 95% CI: 1.53–5.89, P=0.002), but not in patients with glioblastoma (HR: 1.26, 95% CI: 0.76–2.08, P=0.47; P for subgroup difference = 0.03). Results were not statistically different between subgroups according to patient ethnicity, sample size, CD44 detection method, CD44 cutoff, HR estimation, univariate or multivariate analysis, or median follow-up durations (P-values for subgroup difference all >0.10). Conclusion: Higher tumor expression of CD44 may predict poor survival in patients with glioma, particularly in those with WHO stage II–III glioma.

show abstract

Section: Introductionmentioning

confidence: 99%

Expression of CD44 and the survival in glioma: a meta-analysis

Song

et al. 2020

Bioscience Reports

View full text Add to dashboard Cite

show abstract

“…Relevant to this statement, empirically, remarkably fully 13 independent studies just between 2018 and 2020 reported the same findings-that a higher neutrophil to lymphocyte ratio-a relative or absolute neutrophilia-correlated with shorter survival in GB [66][67][68][69][70][71][72][73][74][75][76][77][78]. Few parameters in any cancer have been so oft confirmed.…”

Section: Dapsone Gb and Neutrophilsmentioning

confidence: 85%

Research Supporting a Pilot Study of Metronomic Dapsone during Glioblastoma Chemoirradiation

Kast¹

2021

Medical Sciences

View full text Add to dashboard Cite

This short note presents previous research data supporting a pilot study of metronomic dapsone during the entire course of glioblastoma treatment. The reviewed data indicate that neutrophils are an integral part of human glioblastoma pathophysiology, contributing to or facilitating glioblastoma growth and treatment resistance. Neutrophils collect within glioblastoma by chemotaxis along several chemokine/cytokine gradients, prominently among which is interleukin-8. Old data from dermatology research has shown that the old and inexpensive generic drug dapsone inhibits neutrophils’ chemotaxis along interleukin-8 gradients. It is on that basis that dapsone is used to treat neutrophilic dermatoses, for example, dermatitis herpetiformis, bullous pemphigoid, erlotinib-related rash, and others. The hypothesis of this paper is that dapsone will reduce glioblastomas’ neutrophil accumulations by the same mechanisms by which it reduces dermal neutrophil accumulations in the neutrophilic dermatoses. Dapsone would thereby reduce neutrophils’ contributions to glioblastoma growth. Dapsone is not an ideal drug, however. It generates methemoglobinemia that occasionally is symptomatic. This generation is reduced by concomitant use of the antacid drug cimetidine. Given the uniform lethality of glioblastoma as of 2020, the risks of dapsone 100 mg twice daily and cimetidine 400 mg twice daily is low enough to warrant a judicious pilot study.

show abstract

“…Our finding is consistent with the results of other studies. 12,13 Some researchers found that with the increase of glioma grade, the infiltration of granulocytes increases, and the two are positively correlated. 12 Also, the infiltration of granulocytes and lymphocytes in local tumor inflammation was related to NLR, which represents systemic inflammation.…”

Section: Discussionmentioning

confidence: 99%

“…12,13 Some researchers found that with the increase of glioma grade, the infiltration of granulocytes increases, and the two are positively correlated. 12 Also, the infiltration of granulocytes and lymphocytes in local tumor inflammation was related to NLR, which represents systemic inflammation. 13 Our study further confirmed the correlation between local inflammation and systemic inflammation in glioma.…”

Section: Discussionmentioning

confidence: 99%

<p>Neutrophil-to-Lymphocyte Ratio and Its Changes are Related to Grade II–IV Glioma Recurrence</p>

2020

CMAR

View full text Add to dashboard Cite

Objective: To explore whether the neutrophil-to-lymphocyte ratio (NLR) and its changes are related to tumor recurrence in grade II-IV glioma patients. Methods: One hundred patients who underwent two surgeries (first for diagnosis and the second for recurrence) were retrospectively analyzed. Complete blood count was obtained preoperatively before any treatment. Basic NLR (before the first surgery) and NLR changes were calculated. Tumor recurrence was evaluated by progression-free survival (PFS) using the Kaplan-Meier method. Univariate and multivariate Cox regression analyses were used to determine the potential prognostic factors for PFS. Results: The PFS of patients with high basic NLR (≥4) (median 9 months) was shorter than that of patients with low basic NLR (<4) (median 23 months) (P = 0.004). Univariate and multivariate analyses both showed that basic NLR (before the first surgery) (≥4 vs <4) was an independent predictor of PFS (P = 0.011). The PFS is also varied with NLR changes before two surgeries (P < 0.05). The PFS of patients with two low NLR (<4) at both initial surgical resection and section for tumor recurrence had the longest PSF. The patients with two high NLR (≥4) at both initial surgical resection and section for tumor recurrence had the shortest PSF. The patients with one high NLR (≥4) at initial surgical resection or section for tumor recurrence had an average PSF. Multivariate analysis showed that the change of NLR was of prognostic significance independent of glioma grade. Conclusion: We showed both basic NLR and NLR changes could predict the recurrence of glioma, but the change of NLR is more accurate than that of basic NLR. The current research not only provides a simple and feasible method for clinical judgment of glioma recurrence but also provides a new idea for exploring the mechanism of glioma recurrence.

show abstract

Peripheral blood test provides a practical method for glioma evaluation and prognosis prediction

Cited by 23 publications

References 28 publications

Expression of CD44 and the survival in glioma: a meta-analysis

Expression of CD44 and the survival in glioma: a meta-analysis

Research Supporting a Pilot Study of Metronomic Dapsone during Glioblastoma Chemoirradiation

<p>Neutrophil-to-Lymphocyte Ratio and Its Changes are Related to Grade II–IV Glioma Recurrence</p>

Contact Info

Product

Resources

About